COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies

Laura Gragnani a, 1, Marcella Visentini b, 1, Serena Lorini a, Francesca La Gualana b, Stefano Angelo Santini c, d, Fabio Cacciapaglia e, Antonio Tavoni f, Giovanna Cuomo g, Poupak Fallahi h, Florenzo Iannone e, Alessandro Antonelli i, Milvia Casato b, Anna Linda Zignego b, Clodoveo Ferri h, j, k, 1

a MASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRISMASVE, AOU Careggi, Largo Brambilla, 3, 50134, Florence, Italy
b Department of Translational and Precision Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy
c Department of Basic, Clinical, Intensive and Perioperative Biotechnological Sciences, Catholic University School of Medicine, Largo A. Gemelli, 00168, Rome, Italy
d Synlab Lazio, Via San Polo dei Cavalleri 20, 00159, Rome, Italy
e Clinical Immunology, University of Pisa, Via Paolo Savi, 56126, Pisa, Italy
f UO Reumatologia, AOU Careggi, Largo Brambilla, 3, 50134, Florence, Italy

Rheumatology Clinic ‘Madonna dello Scoglio’, Traversa Mola, 88836, Corone, Crotone, Italy

h Rheumatology, Via Aldovrandi 18, S. Giuliano T., Pisa, Italy
i New Technologies in Medicine and Surgery, University of Pisa, School of Medicine, Via Paolo Savi, 56126, Pisa, Italy
j Rheumatology Unit, University of Modena and Reggio Emilia, School of Medicine, Via del Pozzo 71, 41100, Modena, Italy

ARTICLE INFO

Keywords:
Autoimmune systemic diseases
COVID-19 vaccine
Boosted dose
Humoral response
T-cell response

ABSTRACT

Background: Patients with autoimmune systemic diseases (ASDs) represent a frail population during the ongoing COVID-19 pandemic. The vaccination is the major preventive measure; however, a significant number of ASD patients show an impaired production of anti-COVID-19 neutralizing antibodies (NAb), possibly counterbalanced by adequate T-cell response. The present study aimed at evaluating both humoral and cellular response to COVID-19 vaccine booster dose in this particular setting.

Patients and methods: Serum NAb titer and T-cell response (measuring interferon gamma –IFN–γ release) were evaluated 3 weeks after the COVID-19 vaccine booster dose, in 17 patients (12 F, mean age 68.8 ± 15.3 SD yrs) with different ASDs, compared to 17 healthy controls (HCs).

Results: The analysis excluded one patient reporting symptoms of COVID-19 only after the immunogenicity tests had been performed.

The NAb levels were significantly lower in ASD compared to HCs (p < 0.0001); moreover, patients showed a higher percentage of negative/sub-optimal humoral response (31% vs 0% of HCs; p = 0.0136).

The study of cellular response showed lower levels of IFN-γ for both Ag1 (p = 0.0032) and Ag2 (p = 0.0136) in ASD patients compared to HCs, as well lower rate of adequate T-cell response compared to HCs (50% vs 94%; p = 0.0066).

Disease modifying therapies (DMT) were administered in all patients with deficient NAb production (5/5, 100%), but in only 3/11 (27%) of responders (p = 0.025).

Worthy to note, 3/16 (19%) ASD patients developed neither humoral nor cellular responses, all treated with DMT.

Conclusions: The impaired immunogenicity to COVID-19 vaccine booster and even more the concomitant lack of both humoral and cellular response might represent a high risk for severe COVID-19, particularly in ASD patients undergoing DMT.

1 Corresponding author. Rheumatology, Via Aldovrandi 18, S. Giuliano T., Pisa, Italy.
E-mail address: clferri@unimore.it (C. Ferri).

Received 12 August 2022; Received in revised form 10 September 2022; Accepted 12 September 2022

Available online 13 September 2022

https://doi.org/10.1016/j.jtauto.2022.100164

© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

After more than two years from the identification of the first cases in China [1], the CoRoNaVirus Disease 19 (COVID-19), caused by SARS-CoV-2 infection, continues to claim victims worldwide. Although the introduction of mass vaccination programs in many countries contributed to greatly reduce spreading, disease severity, and deaths, segments of frail population are still vulnerable and at high risk. Patients with autoimmune systemic diseases (ASDs) are considered frail subjects, thus studies regarding vaccination immunogenicity in this setting may suggest possible key tools and strategies against the worse COVID-19 consequences. In this context, different analyses have been performed to ascertain either the COVID-19 overall impact on ASDs [2–4] and the vaccination immunogenicity and safety [5–10]. The reported prevalence of COVID-19 in ASD patients compared to the general population is variable, often increased [3,11]. Conversely, the vaccine-induced humoral response, after a complete vaccination cycle, is significantly attenuated in ASDs compared to healthy controls [5,12]. Even if the booster dose increases the percentage of ASD patients developing a humoral response, a subgroup of them still does not show a protective antibody titer [5,13,14].

To achieve the desired long-lasting immunity, a vaccine should not only evoke a robust humoral response but also drive a strong CD4+ and CD8+ T cell response.

Assessing the ability of ASD patients to build a specific T cell response to COVID-19 vaccination has a great interest to understand if subjects with an impaired humoral response have a partial immune protection.

Nevertheless, there is still controversy regarding the T cell response in the ASD setting due to the variability of the diagnoses and to the different effect of ongoing disease modifying therapies (DMT) on the cellular immunity [15–24].

The majority of the available studies assessed the T cell response among ASD patients after the first 1–2 doses of COVID-19 vaccination [15–17,19,22–24] but results concerning both humoral and cellular post booster immunogenicity are still very limited [14,18,25,26].

Therefore, we aimed at evaluating the humoral and cellular response to the booster dose of COVID-19 vaccine in a group of ASD patients compared to healthy controls (HCs), to ascertain the presence of patients particularly vulnerable to serious COVID-19 even after the third immunization shot.

2. Patients and methods

Immunogenicity of COVID-19 vaccine was evaluated 3 weeks after the booster dose of COVID-19 vaccine, in 17 ASD subjects (12 (71%) females, mean age 68.8 ± 15.3 years) and in 17 age and sex matched HCs without a past exposure to immunosuppressive therapies.

One patient, a 60 years old female affected by SLE (no. 17, Table 1) reported to have had symptoms of COVID-19 prior to the booster dose only after the immunogenicity tests had been performed; since the COVID-19 could have altered the vaccine-induced immune response, the patient was excluded from the following analysis.

Table 1: Humoral and cellular response to COVID-19 vaccine booster in autoimmune systemic diseases.

| Patient | Sex | Age | Diagnosis | DMT (<6 months) | Response to COVID-19 vaccine |
|---------|-----|-----|-----------|-----------------|-----------------------------|
|         |     |     |           | DMT (<6 months) | Humoral                   | Cellular            |             |
|         |     |     |           | DMT (<6 months) | Ag1 | Ag2 |                  |             |
| 1       | F   | 83  | CV        | none            | POS | NEG | NEG              |             |
| 2       | M   | 55  | CV        | RTX + Bendamustine | NEG | NEG | NEG              |             |
| 3       | F   | 83  | CV        | none            | POS | POS | POS              |             |
| 4       | F   | 70  | CV        | none            | POS | POS | POS              |             |
| 5       | F   | 87  | CV        | none            | POS | POS | POS              |             |
| 6       | M   | 79  | CV        | none            | POS | NEG | NEG              |             |
| 7       | M   | 75  | CV        | High-CSs (RTX)  | SUB | NEG | NEG              |             |
| 8       | F   | 57  | SSc       | Low-CSs + MMF   | POS | NEG | NEG              |             |
| 9       | M   | 36  | SSc       | Low-CSs + MMF   | SUB | POS | POS              |             |
| 10      | F   | 86  | SSc       | Low-CSs         | POS | NEG | NEG              |             |
| 11      | F   | 70  | SSc       | HCQ             | POS | POS | POS              |             |
| 12      | F   | 62  | SSc       | AZA             | POS | POS | POS              |             |
| 13      | F   | 64  | SSc       | Low-CSs + MMF   | SUB | NEG | NEG              |             |
| 14      | F   | 54  | RA        | Low-CSs + LFM + JAKi | NEG | POS | POS              |             |
| 15      | F   | 52  | RA        | HCQ             | POS | NEG | NEG              |             |
| 16      | M   | 88  | RA        | Low-CSs + AZA   | POS | POS | POS              |             |
| 17      | F   | 60  | SLE + COVID19* | Low-CSs + AZA | POS | POS | POS              |             |

Table 1 legend: F: Female; M: Male; Ag1: Antigen 1; Ag2: Antigen 2; CV: cryoglobulinemic vasculitis; DMT: disease modifying therapies; SSc: systemic sclerosis; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; RTX: Rituximab; Cs: Corticosteroids; MMF: Mycophenolate mofetil; HCQ: Hydroxychloroquine; AZA: Azathioprine; LFM: Leflunomide; JAKi: JAK-inhibitors. Low-CSs dose: ≤10 mg/day; High-CSs dose: >25 mg/day. *The patient had symptoms of COVID-19 prior to the booster dose, and she reported it only after the immunogenicity tests had been performed; RTX was administered 12 months before the booster shot.

These frail subjects should be tightly monitored for their immune protection and prioritized for the fourth dose of COVID-19 vaccine. Moreover, in the occurrence of SARS-CoV2 infection, treatments with specific monoclonal antibodies and/or antivirals may be highly recommendable.
COVID-19 vaccine was administered to both patients and controls by intramuscular injection in the deltoid muscle according to the manufacturer indications and the Italian national guidelines; all the subjects received BNT162b2 vaccine.

Peripheral blood was collected 3 weeks after the booster dose and was used to assess both humoral and cellular immune response.

The humoral response to COVID-19 vaccines was evaluated by measuring the titer of NAb against SARS-CoV-2 trimeric spike S1/S2 glycoproteins on serum samples, using SARS-CoV-2 IgG II Quant antibody test kit (Abbott Laboratories, Chicago, IL). As recommended by the World Health Organization (WHO), antibody titers are expressed as Binding Antibody Units (BAU)/ml, with a cut-off for positive testing of 7 BAU/ml. A NAb serum titer >7 BAU/ml and <10x upper limit of normal (70 BAU/ml) was classified as suboptimal response.

T cell response was assessed by measuring interferon-gamma (IFN-γ) production by peripheral blood lymphocytes upon SARS-CoV-2 glycoprotein stimulation using the QuantiFERON® SARSCoV-2 Starter Set (Qiagen), an interferon gamma release assay (IGRA). Specimens were processed as per the manufacturer’s guidelines.

Briefly, the assay consists of two Antigen (Ag) tubes, SARS-CoV-2 Ag1 and SARS-CoV-2 Ag2, that use a combination of antigens specific to SARS-CoV-2 to stimulate T cells in heparinized whole blood. QuantiFERON Nil and Mitogen blood collection tubes were used as negative and positive controls, respectively.

Plasma collected after the stimulation was used for IFN-γ detection through a specific QuantiFERON ELISA (Qiagen).

Elevated response was defined as a value of at least 0.15 IU/mL greater than the background IU/mL value from the QuantiFERON SARS-CoV-2 Nil tube [27].

No patients had moderate-severe lymphopenia and/or an alteration of inflammation indexes that are known to affect the sensitivity of QuantiFERON.

### 2.1. Statistical analysis

Data are expressed as mean ± standard error of mean (SEM), or number (percentage) as appropriate. The Student’s T test (Mann-Whitney for paired samples or Wilcoxon test for unpaired samples) was used for comparing means of continuous variables between two groups. Fisher’s exact test was used to compare categorical variables between two groups. All tests were two tailed and a p value < 0.05 was considered significant. Analyses were performed using the GraphPad Software v 9.

### 3. Results

Both humoral and cellular response to COVID-19 booster dose were analyzed in 16 ASD patients and 17 HCs.

The humoral response was significantly lower in ASDs compared to HCs (1909 ± 690.2 vs 10,488 ± 454.3 BAU/ml, p < 0.0001) (Fig. 1, panel A); moreover, 5/16 (31%) ASD patients showed negative/suboptimal response while all the HCs revealed a humoral response (p = 0.0184).

The cellular response, assessed by QuantiFERON IGRA, was analyzed separately for Ag1 and Ag2 as detailed in Fig. 1, panel B.

Regarding Ag1 stimulation, mean INF-γ level was 0.4845 ± 0.2655 IU/mL in ASD subjects and 1.516 ± 0.2218 IU/mL in HCs (p = 0.0032) (Fig. 1, panel B). Similarly, the mean INF-γ level, after Ag2 stimulation, was significantly lower in ASDs compared to HCs (1.333 ± 0.6617 vs 2.371 ± 0.3677 IU/mL, p = 0.0136) (Fig. 1, panel B).

Moreover, ASD patients developed a lower rate of cellular response compared to HCs (8/16, 50% vs 16/17, 94%; p = 0.0066; Table 1).

Of note, 3/16 (19%) ASD patients develop neither humoral nor cellular responses (pts no 2, 7, and 13; Table 1).

Focusing on the therapies administered within the 6 months before the booster dose of vaccine (Table 1), 8/16 (50%) analyzed patients received DMT, while the remaining underwent low doses of corticosteroids (CSs) or hydroxychloroquine (HCQ) (3/16, 19%) or were untreated (5/16, 31%).

A negative/suboptimal humoral response was associated to DMT administration. In fact, 5/5 (100%) patients with deficient NAb production were treated with DMT, while only 3/11 (27%) were on-therapy among the responders (p = 0.025).

Regarding the cellular response, DMTs were administered in half of the patients in both groups of responders and no responders (p = n.s.) (Table 1).

Considering the two types of immune response, we found that all the 3 (100%) patients negative for both humoral and cellular response were on DMT, while 3/7 (43%) with a discordant response and 2/6 (33%) subjects with both positive responses received the therapy.

### 4. Discussion

The present study analyzing the boosting effect of the COVID-19 vaccine third dose in well-defined ASDs revealed a clear-cut reduction of both humoral and cellular response in a significant percentage of patients compared to HCs. The defective immunogenicity was associated with the ongoing DMT frequently employed in these frail patients’
A subgroup of ASD patients still maintains an impaired/absent humoral response, sequences [30]. Nevertheless, even after the booster dose, a subgroup of vaccinated patients, are more protected from severe COVID-19 consequences [28]. Reports highlighted that ASD patients have a significantly higher prevalence of COVID-19 compared to general population [29] as well as that vaccination is the major tool to prevent and fight the COVID-19 pandemic; this is particularly true for frail patients’ populations [28] such as individuals with ASD. Several population. Worthy of note, almost one fifth of the patients examined showed a concomitant absence of either serum NAb and T-cell response to SARS-CoV-2 antigens, all under DMT.

The available literature showed that vaccination is the major tool to control and fight the COVID-19 pandemic; this is particularly true for frail patients’ populations [28] such as individuals with ASD. Several reports highlighted that ASD patients have a significantly higher prevalence of COVID-19 compared to general population [29] as well as that 3-dose vaccinated ASD subjects, compared to unvaccinated or 2-dose vaccinated patients, are more protected from severe COVID-19 consequences [30]. Nevertheless, even after the booster dose, a subgroup of ASD patients still maintains an impaired/absent humoral response, vaccine-based stratification: 29% for BBIBP-CorV vaccine, 32% for Gam-COVID-Vac and AZD1222 vaccine, 32% for BNT162b2 and mRNA-1273 vaccine

| First author | Year, ref | Country | Patients no | Diagnosis | Therapies | Immunogenicity |
|--------------|-----------|---------|-------------|-----------|-----------|---------------|
|              |           |         |             |           |           | Humoral response | Cellular response<sup>α</sup> |
| **After the first doses of COVID-19 vaccine** | | | | | | | |
| Saleem B. 2022 | UK 83 | RA | RTX, anti TNF, anti-IL6, MTX, ABA, Jak inhibitors | MMF | 45% | 53% |
| De Santis M. 2022 | Italy 150 | RA; SSc; SLE; SpA; DM | RA 100% SSc 27% SLE 100% SpA 100% DM 100% | | Impaired cellular response in patients with an impaired humoral response. |
| Bitoun S. 2021 | France 59 | RA; SSc; Vasculites | RTX (24 pts) DMARDs, bDMARDs, MMF, bendamustine, CsS (35 pts) | RTX 29.2% Other immune-suppressors: 80% | CD4 and CD8 cellular responses similar between the two groups and to HCs |
| Farroni C. 2022 | Italy 35 | RA | TNF α inhibitors, DMARD, IL-6 inhibitors, CsS, ABA | nd | 91.4% |
| Prendekhi M. 2021 | UK 42 | SLE; AAV | SLE 7/8 (87.5%); AAV 17/34 (50%) | SLE 2/2 (100%) | Vaccine-based stratification: 20% for BBIBP-CorV vaccine, 32% for Gam-COVID-Vac and AZD1222 vaccine, 32% for BNT162b2 and mRNA-1273 vaccine |
| Szébeni G.J. 2022 | Hungary 89 | RA; SSc; AAV; SjS | CsS, bDMARDs, cDMARDs, Belimumab | 55% for BBIBP-CorV vaccine, 53% for Gam-COVID-Vac and AZD1222 vaccine, 81% for BNT162b2 and mRNA-1273 vaccine |
| Oyaert M. et al. 2022 | Belgium 21 | RA, SSc, SLE, PsA, AAV, polymyositis, IgA granulomatosis | RTX, DMARD, CsS, MTX, belimumab, adalimumab, | 11/21 (52.4%) | 9/21 (42.9%) |
| Steiro Santos C. et al. 2022 | Spain | I cohort (ongoing immune-suppressors):100 II cohort (no immune-suppressors): 47 | I cohort: MTX, AZA, MMF, LFM and/or bDMARDs (Belimumab, ABA, RTX) II cohort: Non-steroidal anti-inflammatory drugs and/or infliximab, tocilizumab, anakinra | I cohort Seroconversion: 55% II cohort Seroconversion: 80% | Th1 response 52% CD8 response 77% |
| Marty P.K. 2022 | USA 17 | AAV | 11 B-cell depleted 8 B-cell recovered | 0% | 90.9% |

| **After the booster dose of COVID-19 vaccine** | | | | | | |
| Corradini P. et al. 2022 | Italy 37 | AAV, SSc, mixed connective tissue disease, SLE, pSS, RA, polymyositis, and RA | MTX, MMF, AZA, cyclosporine, RTX, CsS | 90% | 89.2% |
| Firinu D. et al. 2022 | Italy 31 | RA, SLE, Connective Tissue Disease; MS | RTX; OCRE; ADA; ETN; MTX; MMF; cLSDMARDs | 55% among the RTX group, 100% in IMID (immune-mediated inflammatory diseases, naive to RTX) | 21 (68%) |
| Azzolini E. et al. 2022 | Italy 30 | PA/SpA/AS, RA, DM, pSS, SSc | MTX, MMF | 96.6% | 80% Ag1 83.3% Ag2 |
| Jysym L. et al. 2022 | Norway 49 | RA | All treated with RTX | 16.3% | 100% (evaluated in 12.49) |

**Table 2** legend: Abbreviations: RA: rheumatoid arthritis; SSc: systemic sclerosis; SLE: systemic lupus erythematosus; AAV, ANCA-associated vasculitis; PsA: Psoriatic arthritis; SpA: Spondyloarthritis; A5 ankylosing spondylitis; DM: Dermatomyositis; pSS: Primary Sjogren’s syndrome; MS: Multiple Sclerosis; IMID: immune-mediated inflammatory diseases; RTX: Rituximab; MTX: Methotrexate; DMARDs: Disease Modifying Anti-Rheumatic Drugs; bDMARDs: Biological disease modifying anti-rheumatic drugs; CsS: Corticosteroids; LFM: Leflunomide AZA: Azathioprine; MMF: Mycophenolate mofetil; ABA: Abatacept; OCRE: ocrelizumab; ADA: adalimumab; ETN: etanercept; HCs: Healthy Controls; pts: patients. <sup>α</sup> Cellular response was evaluated by different methods.
mainly (but not exclusively), due to concomitant DMT [5,13,14].

On the other hand, previous observations in multiple sclerosis patients on anti-CD20 therapy [31] suggested that an impaired humoral response after the booster dose of COVID-19 vaccine could be compensated by an effective T-cell response; however, studies focusing on well-defined ASD are still very limited and partly conflicting [18,25,26] as briefly reported in Table 2.

As we recently reported, although a percentage of non-responder ASD patients seroconverted after the booster dose, a subgroup of subjects with absent or suboptimal NAB titer persist [32]. This observation concerning the humoral response to COVID-19 vaccine is in line with the results described in the present analysis, as 31% of patients have a deficient humoral response after the booster dose. Furthermore, by analyzing the T-cell response we found that half of the ASD patients did not develop a cellular immunity while only one HC showed an INF-γ level under the positivity cut-off. Although the presence of different diagnoses and the variability of DMT make very difficult a comparison with the few previously published results [14,18,25,26], the percentage of T-cell response we found is comparable to that reported by Firinu and colleagues that stratified ASD patients based on different treatments [18]. They found 50% of no response in subjects undergoing MTX (with or without anti-TNF), MMF, and/or low doses of CsA while 21% of those on anti-CD20 had no T-cell response [18].

Azzolini and coworkers analyzed humoral and cellular immunity in different settings of immunocompromised patients, including a group affected by rheumatic diseases [25]. Their follow-up study of both responses, from the first vaccine shot to two weeks after the third dose, did not find significant improvement of cellular immunity since many patients remained below the positivity cut-off [25]. However, a comparison with our results is hard since the percentage of patients lacking in T-cell response is not reported.

Despite the clinical and therapeutic differences among the evaluated patients’ series, our findings are quite consistent with the above observations (35); given the similar DMT, they seem to suggest that the booster dose of COVID-19 vaccine could be more effective on the humoral response.

In addition, while the humoral response seems to be linked to the use of DMT [6,32], 50% of ASD patients with impaired cellular response did not receive such treatments.

Interestingly, 19% of patients were negative for both humoral and cellular response and all of them were on DMT. This is an alarming finding since a non-negligible percentage of ASD patients do not develop any kind of immune protection even after the booster dose of COVID-19 vaccine.

We excluded from the analysis a woman that had a COVID-19 before receiving the third dose; the NAB titer as well as the INF-γ level were higher than the mean values recorded in the analyzed patients, despite of an DMT. This is in line with previous observations pointing out the higher immunogenic power on both humoral and cellular response of COVID-19 compared to the vaccination [33].

5. Conclusions

In conclusion, although the boosting effects of third dose of COVID-19 vaccine in ASD patients are evident on humoral response, more extensive studies are needed to clarify its effects on T-cellular immunity. The present study suggests that half of ASD patients do not develop a cellular response and that a subgroup of them did not mount an efficient humoral response; consequently, this subgroup with concomitant absence of both humoral and cellular immunoreactivity might be at high risk for SARS-CoV2 infection and severe COVID-19 manifestations.

Overall, these preliminary results stress the importance to test the immune protection status of ASD patients, even after the third shot of the COVID-19 vaccination. This may be particularly opportune for patients undergoing DMT, including high dose corticosteroids, and with major risk factors for worse COVID-19 outcomes (older age, lung fibrosis, and/or comorbidities) [34]. These subjects might be prioritized for the fourth dose of COVID-19 vaccine, hopefully with new generation vaccines; in addition, it could be opportune to adopt adequate social distancing measures, as well preemptive treatments with monocular anti-SARS-CoV-2 antibody, and/or novel antiviral drugs, individually tailored considering the whole patient’s clinical conditions.

Credit author statement

LG*, MV* and CF contributed to conceptualisation, writing – original draft, and writing– review & editing, supervision and methodology; SL, FLG and SAS contributed to investigation, formal analysis; FC and AT contributed to investigation, GC and PF contributed to data curation, FI, AA, MC and ALZ reviewed and edited the paper.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

Data will be made available on request.

References

[1] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020) 497–506.
[2] F. R. S. S. C. I. c. a. contributors, Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients, Ann. Rheum. Dis. 80 (4) (2021) S27–S530, https://doi.org/10.1136/annrheumdis-2020-218310.
[3] D.D. Freites Nuínez, L. Leon, A. Muñeces, L. Rodríguez-Rodríguez, J. Font Urgelles, A. Madrid García, et al., Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases, Ann. Rheum. Dis. 79 (2020) 1393–1399.
[4] C. Ferri, D. Giuggioli, V. Raimondo, P. Fallahi, A. Antonelli, C.-A.I.S. Group, COVID-19 in Italian patients with rheumatic autoimmune systemic diseases, Ann. Rheum. Dis. (2020).
[5] C. Ferri, F. Ursini, L. Gragnani, V. Raimondo, D. Giuggioli, R. Fori, et al., Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups, J. Autoimmun. 125 (2021), 102744.
[6] Y. Braun-Moscovici, M. Kaplan, M. Braun, D. Markovits, S. Giryès, K. Toledano, et al., Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2, Ann. Rheum. Dis. 80 (2021) 1317–1321.
[7] M. Gian Francesco, K.L. Hyrich, S. Al-Adey, L. Carmona, M.I. Danila, L. Gosec, et al., Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann. Rheum. Dis. 79 (2020) 859–866.
[8] J. Avouac, E. Drumez, E. Hochulla, R. Seror, S. Georgini-Lavialie, S. El Mahou, et al., COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study, Lancet Rheumatol. 3 (2021) e419–e426.
[9] U.M. Geisen, D.K. Berner, F. Tran, M. Sümübil, L. Vulliреде, M. Ciripio, et al., Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort, Ann. Rheum. Dis. 80 (2021) 1306–1311.
[10] J.A. Rudy, C.M. Connolly, B.J. Boyarsky, W.A. Werbel, L. Christopher-Stine, J. Garonzik-Wang, et al., High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases, Ann. Rheum. Dis. (2020) 1351–1352.
[11] M. Rutter, P.C. Lanyon, M.J. Grainge, R. Hubbard, E. Peach, M. Bythell, et al., COVID-19 Infection, Admission and Death Amongst People with Rare Autoimmune Rheumatic Disease in England. Results from the RECOVER Project, Rheumatology, Oxford, 2021.
[12] L. Boekel, M. Steenhuis, F. Hooijberg, Y.R. Beten, Z.L.E. van Kempen, L. Y. Kummer, et al., Antibody development after COVID-19 vaccination in patients with autoimmune diseases in The Netherlands: a study of data from two prospective cohort studies, Lancet Rheumatol. (2021).
[13] S.W. Syversen, I. Jysum, A.T. Tvetter, T.T. Tran, J. Sexton, S.A. Provan, et al., Immunogenicity and Safety of Standard and Third Dose SARS-CoV-2 Vaccination in Patients on Immunosuppressive Therapy, Arthritis Rheumatol., 2022.
[14] I. Jysium, H. Kared, T.T. Tran, A.T. Tveter, S.A. Provan, J. Sexton, et al., Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study, Lancet Rheumatol. 4 (2022) e177–e187.

[15] S. Bitoun, J. Henry, D. Denjardins, C. Vauloup-Fellous, N. Dib, R. Belkhir, et al., Rituximab Impairs B Cell Response but Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases, Arthritis Rheumatol, 2021.

[16] M. Prendecki, C. Clarke, H. Edwards, S. McIntyre, P. Mortimer, S. Gleeson, et al., Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression, Ann. Rheum. Dis. 80 (2021) 1322–1329.

[17] M. Oyaert, M.A. De Scheerder, S. Van Herrewege, G. Laureys, S. Van Asche, M. Cambron, et al., Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients, Front. Immunol. 13 (2022), 858399.

[18] D. Firino, G. Fenu, G. Sanna, G.A. Costanzo, A. Perra, M. Campagna, et al., Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy, J. Autoimmun. 131 (2022), 102848.

[19] M. De Santis, F. Motta, N. Isailovic, M. Clementi, E. Criscuolo, N. Clementi, et al., Prevalence and death rate of COVID-19 in systemic autoimmune diseases in the first three pandemic waves. Relationship to disease subgroups and ongoing therapies, Curr. Pharmaceut. Des. (2022).

[20] B. Saleem, R.L. Ross, L.A. Bissell, A. Aslam, K. Mankia, L. Duquenne, et al., Effectiveness of SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis (RA) on DMARDs: as Determined by Antibody and T Cell Responses, vol. 8, RMD Open, 2022.

[21] P.K. Marty, V.P. Van Keulen, C.L. Erskine, M. Shah, A. Hummel, M. Stachowiak, et al., Antigen specific humoral and cellular immunity following SARS-CoV-2 vaccination in ANCA-associated vasculitis patients receiving B-cell depleting therapy, Front. Immunol. 13 (2022), 834981.

[22] C. Farroni, A. Picchianti-Diamanti, A. Aiello, E. Nicastri, B. Laganò, A. Agrati, et al., kinetics of the B- and T-cell immune responses after 6 Months from SARS-CoV-2 mRNA vaccination in patients with rheumatoid arthritis, Front. Immunol. 13 (2022), 846753.

[23] G.J. Szebeni, N. Gomes, D. Honfi, E. Szabó, P. Neuperger, J. Balog, et al., Humoral and cellular immunogenicity and safety of five different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases in remission or with low disease activity and in healthy controls: a single center study, Front. Immunol. 13 (2022), 846248.

[24] C. Sieiro Santos, S. Calleja Antolin, C. Moriano Morales, J. Garcia Herrero, E. Diez Alvarez, F. Ramos Ortega, et al., Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases, RMD Open 8 (2022).

[25] E. Azzolini, C. Pozzi, L. Germagnoli, B. Oresta, N. Carrilglo, M. Calleri, et al., mRNA COVID-19 Vaccine Booster Fosters B- and T-Cell Responses in Immunocompromised Patients, vol. 5, Life Sci Alliance, 2022.

[26] P. Corradi, C. Agrati, G. Apolone, A. Mantovani, D. Giannarelli, V. Marasco, et al., Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4PRAL study, Clin. Infect. Dis. (2022).

[27] S. Jaganathan, P. Steiber, S.N. Rao, V. Nikolayevsky, D. Manisiero, N. Allen, et al., Preliminary evaluation of QuantIFERON SARS-CoV-2 and qIPAtech anti-SARS-CoV-2 total test in recently vaccinated individuals, Infect. Dis. Ther. 10 (2021) 2765–2776.

[28] P. Nordstrom, M. Ballin, A. Nordstrom, Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden, Lancet 399 (2022) 814–821.

[29] C. Ferri, V. Raimondo, L. Gragnani, D. Giuggioli, L. Dagna, A. Tavoni, et al., Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in ANCA-associated vasculitis patients receiving B-cell depleting therapy, J. Autoimmun. 131 (2022), 102866.

[30] A. Bieber, I. Sagy, L. Novack, S. Brikman, R. Abuhasira, S. Ayalon, et al., Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients, Front. Immunol. 13 (2022), 858399.

[31] S.P. Gadani, M. Reyes-Mantilla, L. Jank, S. Harris, M. Douglas, M.D. Smith, et al., Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy, ElifeMedicine 73 (2021), 103636.

[32] C. Ferri, L. Gragnani, V. Raimondo, M. Visentini, D. Giuggioli, S. Lorini, et al., Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases, J. Autoimmun. 131 (2022), 102866.

[33] R. Kernt, S.I. Richardson, T. Moyo-Gwete, T. Hermanus, M.B. Tincho, N. Benede, et al., Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner, Cell Host Microbe 29 (2021) 1611–1619, e5.

[34] C. Ferri, D. Giuggioli, V. Raimondo, L. Dagna, V. Riccieri, E. Zanatta, et al., COVID-19 and systemic sclerotic clinicopathological implications from Italian nationwide survey study, Lancet Rheumatol. 3 (2021) e166–e168.